MCID: TRP002
MIFTS: 49

Tropical Spastic Paraparesis

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Tropical Spastic Paraparesis

MalaCards integrated aliases for Tropical Spastic Paraparesis:

Name: Tropical Spastic Paraparesis 12 74 53 15 17 71
Tropical Spastic Paraplegia 12 32
Paraparesis, Tropical Spastic 44
Paraparesis Tropical Spastic 54
Htlv-Associated Myelopathy 12
Tropical Spastic Paralysis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:321
MeSH 44 D015493
SNOMED-CT 67 45129002
ICD10 32 G04.1
UMLS 71 C0030481

Summaries for Tropical Spastic Paraparesis

NINDS : 53 For several decades the term “tropical spastic paraparesis” (TSP) has been used to describe a chronic and progressive disease of the nervous system that affects adults living in equatorial areas of the world and causes progressive weakness, stiff muscles, muscle spasms, sensory disturbance, and sphincter dysfunction. The cause of TSP was obscure until the mid-1980s, when an important association was established between the human retrovirus — human T-cell lymphotrophic virus type 1 (also known as HTLV-1) — and TSP. TSP is now called HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP. The HTLV-1 retrovirus is thought to cause at least 80 percent of the cases of HAM/TSP by impairing the immune system. In addition to neurological symptoms of weakness and muscle stiffness or spasms, in rare cases individuals with HAM/TSP also exhibit uveitis (inflammation of the uveal tract of the eye), arthritis (inflammation of one or more joints), pulmonary lymphocytic alveolitis (inflammation of the lung), polymyositis (an inflammatory muscle disease), keratoconjunctivitis sicca (persistent dryness of the cornea and conjunctiva), and infectious dermatitis (inflammation of the skin). The other serious complication of HTLV-1 infection is the development of adult T-cell leukemia or lymphoma. Nervous system and blood-related complications occur only in a very small proportion of infected individuals, while most remain largely without symptoms throughout their lives. The HTLV-1 virus is transmitted person-to-person via infected cells: breast-feeding by mothers who are seropositive (in other words, have high levels of virus antibodies in their blood), sharing infected needles during intravenous drug use, or having sexual relations with a seropositive partner. Less than 2 percent of HTLV-1 seropositive carriers will become HAM/TSP patients.

MalaCards based summary : Tropical Spastic Paraparesis, also known as tropical spastic paraplegia, is related to htlv-1 associated myelopathy/tropical spastic paraparesis and spastic paraparesis. An important gene associated with Tropical Spastic Paraparesis is CNTN2 (Contactin 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pentoxifylline and Zidovudine have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and eye, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Disease Ontology : 12 A viral infectious disease that results in inflammation located in spinal cord, has material basis in Human T-lymphotropic virus 1, which is transmitted by sexual contact, and transmitted by breast feeding. The infection has symptom spastic weakness of both legs, has symptom muscle stiffness, has symptom sensory disturbance, and has symptom spasms.

Wikipedia : 74 Tropical spastic paraparesis (TSP), is a medical condition that causes weakness, muscle spasms, and... more...

Related Diseases for Tropical Spastic Paraparesis

Diseases related to Tropical Spastic Paraparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 459)
# Related Disease Score Top Affiliating Genes
1 htlv-1 associated myelopathy/tropical spastic paraparesis 33.5 IFNL3 HLA-B HLA-A
2 spastic paraparesis 32.6 IL10 IFNL3 HLA-B HLA-A
3 adult t-cell leukemia 31.4 NFKBIA IL2RA IL2 FOXP3 CNTN2
4 t-cell adult acute lymphocytic leukemia 31.2 IL2RA IL2 FOXP3 CNTN2
5 myelitis 31.0 MMP9 IL6 IL10
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.8 IL10 IFNG FOXP3
7 mumps 30.6 IL6 IL2 IL10 IFNG
8 spinal cord disease 30.6 IL6 IL2 IL10 CNTN2
9 myositis 30.6 IL6 IL2 IFNG HLA-B
10 measles 30.5 IL6 IL2RA IL2 IFNG HLA-B HLA-A
11 dermatitis 30.5 IL6 IL2RB IL2 IL10 IFNG FOXP3
12 purpura 30.4 IL6 IL10 IFNG
13 thyroiditis 30.4 IL6 IL2 IL10 IFNG FOXP3
14 t-cell lymphoblastic leukemia/lymphoma 30.4 NFKBIA JUN IL2RB IL2RA IL2 FOXP3
15 candidiasis 30.4 IL6 IL2 IL10 IFNG
16 peripheral nervous system disease 30.4 MMP9 JUN IL6 IL2 IL10 IFNG
17 chickenpox 30.4 IL6 IL2 IL10 IFNG
18 subacute sclerosing panencephalitis 30.4 IL6 IL2 IL10 IFNG
19 schistosomiasis 30.4 IL2 IL10 IFNG CCL3
20 herpes zoster 30.4 IL2 IL10 IFNG HLA-B HLA-A
21 toxoplasmosis 30.3 IL6 IL10 IFNG CCL3
22 central nervous system disease 30.2 MMP9 IL6 IFNG CXCR3
23 uveitis 30.2 IL6 IL2RA IL2 IL10 IFNG HLA-B
24 graft-versus-host disease 30.1 IL6 IL2 IL10 IFNG HLA-B HLA-A
25 prostatitis 30.1 IL6 IL2 IL10 FOXP3 CCL3
26 acquired immunodeficiency syndrome 30.1 IL6 IL2RB IL2RA IL2 IL10 IFNG
27 lichen planus 30.1 IL6 IL2 IL10 IFNG CXCR3
28 cystitis 30.1 JUN IL6 IL2 CXCR3
29 cutaneous t cell lymphoma 30.1 IL2RB IL2RA IL2 IFNG CXCR3
30 disease by infectious agent 30.0 IL6 IL2RB IL2 IL10 IFNG CCL3
31 nervous system disease 29.9 MMP9 JUN IL6 IL2 IL10 IFNG
32 mycosis fungoides 29.9 IL2RB IL2RA IL2 IFNG FOXP3 CXCR3
33 osteoporosis 29.8 MMP9 JUN IL6 IL2 IL10 IFNG
34 rubella 29.8 TRIM5 IL6 IL2 IL10 IFNG HLA-B
35 lung disease 29.8 MMP9 IL6 IL10 IFNG CXCR3 CCL3
36 alopecia areata 29.8 IL6 IL2RA IL2 IL10 IFNG HLA-B
37 skin disease 29.7 IL6 IL2 IL10 IFNG HLA-B FOXP3
38 psoriasis 29.5 KIR2DL3 IL6 IL2RA IL2 IL10 IFNG
39 human immunodeficiency virus type 1 29.3 TRIM5 NFKBIA IL2 IL10 IFNG HLA-B
40 systemic lupus erythematosus 28.9 NFKBIA MMP9 IL6 IL2RB IL2RA IL2
41 autoimmune disease 28.9 TNFRSF18 MMP9 JUN IL6 IL2RA IL2
42 multiple sclerosis 28.7 MMP9 IL6 IL2RB IL2RA IL2 IL10
43 immune deficiency disease 27.5 TRIM5 NFKBIA JUN IL6 IL2RB IL2RA
44 myelopathy, htlv-1-associated 12.0
45 retrovirus-associated myelopathy 11.5
46 human t-cell leukemia virus type 1 11.4
47 leukemia, t-cell, chronic 11.0
48 spasticity 10.7
49 leukemia 10.6
50 syphilis 10.5

Graphical network of the top 20 diseases related to Tropical Spastic Paraparesis:



Diseases related to Tropical Spastic Paraparesis

Symptoms & Phenotypes for Tropical Spastic Paraparesis

MGI Mouse Phenotypes related to Tropical Spastic Paraparesis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CXCR3 FOXP3 HLA-A IFNG IL10 IL2
2 endocrine/exocrine gland MP:0005379 10.02 FOXP3 HLA-A IFNG IL10 IL2 IL2RA
3 immune system MP:0005387 9.97 CXCR3 FOXP3 HLA-A IFNG IL10 IL2
4 respiratory system MP:0005388 9.61 CXCR3 FOXP3 IFNG IL10 IL2 IL2RA
5 vision/eye MP:0005391 9.28 FOXP3 IFNG IL10 IL2 IL2RA IL6

Drugs & Therapeutics for Tropical Spastic Paraparesis

Drugs for Tropical Spastic Paraparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
2
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
3
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
4
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
5
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
6
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
7 Protective Agents Phase 3
8 Radiation-Protective Agents Phase 3
9 Antioxidants Phase 3
10 Phosphodiesterase Inhibitors Phase 3
11 Platelet Aggregation Inhibitors Phase 3
12 Vasodilator Agents Phase 3
13 Anti-HIV Agents Phase 2, Phase 3
14 Anti-Infective Agents Phase 2, Phase 3
15 Antimetabolites Phase 2, Phase 3
16 Reverse Transcriptase Inhibitors Phase 2, Phase 3
17 Antiviral Agents Phase 2, Phase 3
18 Anti-Retroviral Agents Phase 2, Phase 3
19 Immunologic Factors Phase 2, Phase 3
20 Immunosuppressive Agents Phase 2, Phase 3
21 Antifungal Agents Phase 2, Phase 3
22 Cyclosporins Phase 2, Phase 3
23 Calcineurin Inhibitors Phase 2, Phase 3
24
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
25
Infliximab Approved Phase 2 170277-31-3
26 interferons Phase 2
27 Adjuvants, Immunologic Phase 2
28 Interferon-beta Phase 2
29 Dermatologic Agents Phase 2
30 Antirheumatic Agents Phase 2
31 Gastrointestinal Agents Phase 2
32 Immunoglobulins Phase 1
33 Antibodies Phase 1
34 Antibodies, Monoclonal Phase 1
35
Valproic acid Approved, Investigational 99-66-1 3121
36 Raltegravir Potassium Early Phase 1
37 HIV Integrase Inhibitors Early Phase 1
38 Integrase Inhibitors Early Phase 1
39 Anticonvulsants
40 Neurotransmitter Agents
41 Psychotropic Drugs

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
2 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
3 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
4 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine;Placebos
5 The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP Completed NCT00773292 Phase 2, Phase 3 ciclosporin
6 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
7 Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
8 An Open, Non-randomised Pilot Study of Anti-TNF-alpha Therapy in Early or Progressing HAM/TSP Terminated NCT00823641 Phase 2 Infliximab
9 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
10 Evaluation of the MP Diagnostics HTLV Blot 2.4 Unknown status NCT01467024
11 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
12 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
13 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
14 A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica Completed NCT00340821
15 Combined Clinical, Immunological and Virological Assessment of Patients With Multiple Sclerosis (MS) Completed NCT00001156
16 Evaluation of the MP Diagnostics HTLV Blot 2.4 Completed NCT03146013
17 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
18 Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP) Recruiting NCT00001778
19 Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP Terminated NCT00519181 Valproic Acid

Search NIH Clinical Center for Tropical Spastic Paraparesis

Cochrane evidence based reviews: paraparesis, tropical spastic

Genetic Tests for Tropical Spastic Paraparesis

Anatomical Context for Tropical Spastic Paraparesis

MalaCards organs/tissues related to Tropical Spastic Paraparesis:

40
T Cells, Spinal Cord, Eye, Endothelial, B Cells, Thymus, Monocytes

Publications for Tropical Spastic Paraparesis

Articles related to Tropical Spastic Paraparesis:

(show top 50) (show all 1595)
# Title Authors PMID Year
1
Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy. 54 61
18639344 2008
2
High production of RANTES and MIP-1alpha in the tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). 54 61
17588676 2007
3
Blockade of IL-2 receptor suppresses HTLV-I and IFN-gamma expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 61 54
17409595 2007
4
Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. 54 61
16879249 2006
5
Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. 54 61
16652169 2006
6
Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. 61 54
16387851 2006
7
Involvement of p38 MAPK signaling pathway in IFN-gamma and HTLV-I expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 54 61
15652420 2005
8
Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). 54 61
15465610 2004
9
TIMPs and MMPs expression in CSF from patients with TSP/HAM. 61 54
12697269 2003
10
Detection of myelin basic protein in cerebrospinal fluid and serum from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 54 61
12564844 2002
11
Detection of myelin basic protein in cerebrospinal fluid. 54 61
12465458 2002
12
High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 61 54
11964301 2002
13
Up-regulation of interleukin-12 receptor expression in peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 54 61
11959151 2002
14
IRF-4 activities in HTLV-I-induced T cell leukemogenesis. 61 54
11846984 2002
15
IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. 61 54
11717409 2001
16
How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis? 54 61
11080816 2000
17
[Increased activity of metalloproteinases and their inhibitors in cerebrospinal fluid of patients with tropical spastic paraparesis]. 61 54
11016056 2000
18
Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. 54 61
10491011 1999
19
Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients. 61 54
10430056 1999
20
HTLV-I-infected T cells evade the antiproliferative action of IFN-beta. 54 61
10329542 1999
21
Gelatinase activity of matrix metalloproteinases in the cerebrospinal fluid of various patient populations. 54 61
10604277 1999
22
Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. 54 61
9633766 1998
23
Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. 54 61
9482906 1998
24
Costimulation of cytokine gene expression in T cells by the human T leukemia/lymphotropic virus type 1 trans activator Tax. 61 54
8648737 1996
25
Sequence analysis of human T cell lymphotropic virus type I (HTLV-I) Env genes amplified from central nervous system tissues of patients with HTLV-I-associated myelopathy or leukemia. 54 61
8778566 1995
26
Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. 54 61
8301322 1994
27
Virion-associated trans-regulatory protein of human T-cell leukemia virus type I. 54 61
1540409 1992
28
Failure to demonstrate human T cell lymphotropic virus type I in multiple sclerosis patients. 61 54
2189023 1990
29
An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. 61
32835825 2021
30
Human T-cell leukemia virus type 1 infection among Japanese immigrants and their descendants living in Southeast Brazil: A call for preventive and control responses. 61
33544713 2021
31
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. 61
32054656 2021
32
Pain, psychoaffective symptoms, and quality of life in human T cell lymphotropic virus type 1 (HTLV-1): a cross-sectional study. 61
33405200 2021
33
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy. 61
33423163 2021
34
Decrease in naïve T cell production due to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) development. 61
33338979 2021
35
Identification of dysregulated pathways underlying HTLV-1-associated myelopathy/tropical spastic paraparesis through co-expression network analysis. 61
33405203 2021
36
Spirituality as Strategies for Coping With Tropical Spastic Paraparesis: Results of Focus Group. 61
33417057 2021
37
Intrinsic and Extrinsic Cell Apoptotic Pathways in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Systematic Review. 61
33470891 2021
38
Therapeutic effects of virtual reality video gaming on functional mobility, balance, and gait speed in individuals with tropical spastic paraparesis: A randomized crossover clinical trial. 61
33533820 2021
39
Status of humoral and cellular immune markers in human T-cell lymphotropic virus type 1 (HTLV-1) asymptomatic carriers in northeastern Iran, Mashhad. 61
33025348 2020
40
Extracellular Vesicles in HTLV-1 Communication: The Story of an Invisible Messenger. 61
33322043 2020
41
The E3/E4 ubiquitin conjugation factor UBE4B interacts with and ubiquitinates the HTLV-1 Tax oncoprotein to promote NF-κB activation. 61
33362245 2020
42
Effectiveness and safety of non-tumor necrosis factor inhibitor therapy for anti-human T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis. 61
33161771 2020
43
Limitations in daily activities, risk awareness, social participation, and pain in patients with HTLV-1 using the SALSA and Participation scales. 61
32941806 2020
44
Dietary Intake and Serum Selenium Levels Influence the Outcome of HTLV-1 Infection. 61
33169347 2020
45
Analysis of a within-host HIV/HTLV-I co-infection model with immunity. 61
33157165 2020
46
Phylogenetic and phylodynamic study of Human T-cell lymphotropic virus Type 1 (HTLV-1) in Iran. 61
32561293 2020
47
Effectiveness of virtual reality games for falls, postural oscillations, pain and quality of life of individual HAM/TSP: a randomized, controlled, clinical trial. 61
32737862 2020
48
Health state utility values in people living with HTLV-1 and in patients with HAM/TSP: The impact of a neglected disease on the quality of life. 61
33064742 2020
49
Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
32705480 2020
50
Spasticity distribution and severity in individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
33021698 2020

Variations for Tropical Spastic Paraparesis

Expression for Tropical Spastic Paraparesis

Search GEO for disease gene expression data for Tropical Spastic Paraparesis.

Pathways for Tropical Spastic Paraparesis

Pathways related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TRIM5 TNFRSF18 NFKBIA MMP9 KIR2DL3 JUN
2
Show member pathways
13.88 TNFRSF18 NFKBIA JUN IL6 IL2RB IL2RA
3
Show member pathways
13.75 TNFRSF18 NFKBIA JUN IL6 IL2RB IL2RA
4
Show member pathways
13.61 TNFRSF18 NFKBIA JUN IL6 IL2RB IL2RA
5
Show member pathways
13.47 TNFRSF18 IL6 IL2RB IL2RA IL2 IL10
6
Show member pathways
13.37 TNFRSF18 NFKBIA JUN IL6 IL2RB IL2RA
7
Show member pathways
13.24 TRIM5 TNFRSF18 MMP9 IL6 IL2RB IL2RA
8
Show member pathways
13.13 NFKBIA MMP9 JUN IL6 IL2 IL10
9
Show member pathways
13.05 IL6 IL2RB IL2RA IL2 HLA-B HLA-A
10
Show member pathways
13.02 TRIM5 NFKBIA JUN IL6 HLA-B HLA-A
11 12.91 NFKBIA MMP9 JUN IL6 IL2RB IL2RA
12
Show member pathways
12.89 KIR2DL3 IL6 IL2RA IL2 IL10 IFNG
13
Show member pathways
12.87 NFKBIA JUN IL6 IL2RB IL2RA IL2
14
Show member pathways
12.85 NFKBIA JUN IL6 IL2RB IL2RA IL2
15 12.84 NFKBIA IL6 IFNG HLA-B HLA-A
16
Show member pathways
12.72 NFKBIA JUN IL2RA IL2 IL10 IFNG
17
Show member pathways
12.68 NFKBIA JUN IL6 IL2 IL10 IFNG
18
Show member pathways
12.65 NFKBIA IL6 IL2 IL10 IFNG
19 12.64 TNFRSF18 NFKBIA IL2RB IL2RA IL2 IL10
20
Show member pathways
12.61 KIR2DL3 JUN IL2 IFNG HLA-B HLA-A
21
Show member pathways
12.6 NFKBIA JUN IL6 IL2RB IL2RA IL2
22
Show member pathways
12.51 IL6 IL2RB IL2RA IL2 IL10 IFNL3
23
Show member pathways
12.48 NFKBIA JUN IL2RA IL2
24
Show member pathways
12.47 NFKBIA JUN IL2RB IL2RA IL2
25 12.45 IL2RB IL2RA HLA-B HLA-A
26
Show member pathways
12.43 IL6 IL2RB IL2RA IL2 IL10 CXCR3
27
Show member pathways
12.42 NFKBIA MMP9 JUN IL6 IFNG
28 12.38 NFKBIA JUN IL6 IL2RB IL2RA IL2
29
Show member pathways
12.36 IL6 IL2RA IL2 IL10 IFNG HLA-B
30
Show member pathways
12.35 NFKBIA JUN IL6 IFNG
31 12.35 NFKBIA JUN HLA-B HLA-A
32
Show member pathways
12.32 NFKBIA JUN IL10 IFNG
33
Show member pathways
12.3 NFKBIA JUN IL6 IL2 IL10
34
Show member pathways
12.25 NFKBIA JUN IL6 IFNG
35 12.19 NFKBIA JUN IL6 IL2 IL10
36
Show member pathways
12.17 JUN IL2RB IL2RA IL2 IFNG
37
Show member pathways
12.1 NFKBIA JUN IL2RA IL2
38 12.1 IL6 IL2RB IL2RA IL2 IL10 IFNG
39 12.09 MMP9 IL6 IL2 IFNG
40 12.05 NFKBIA MMP9 JUN IL6
41 12.03 JUN IL6 IFNG CCL3
42 11.96 JUN IL6 IFNG CCL3
43 11.9 JUN IL6 IL2 IFNG
44
Show member pathways
11.88 JUN IL6 IL2 IL10 IFNG
45
Show member pathways
11.87 JUN IL2RA IL2 IFNG FOXP3
46
Show member pathways
11.85 NFKBIA JUN IL2
47 11.85 IL6 IL2 IL10 IFNG
48 11.8 JUN IL6 IL10
49
Show member pathways
11.8 IL2RB IL2RA IL2 FOXP3
50 11.79 TNFRSF18 IL6 IL2RA IL10 FOXP3

GO Terms for Tropical Spastic Paraparesis

Cellular components related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 IL2RB IL2RA HLA-B HLA-A CXCR3 CNTN2
2 MHC class I protein complex GO:0042612 9.16 HLA-B HLA-A
3 interleukin-2 receptor complex GO:0005893 8.62 IL2RB IL2RA

Biological processes related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 NFKBIA JUN IL6 IL2 IL10 FOXP3
2 positive regulation of transcription, DNA-templated GO:0045893 10.07 TRIM5 NFKBIA JUN IL6 IL10 FOXP3
3 defense response to virus GO:0051607 9.91 TRIM5 IL6 IFNL3 IFNG
4 negative regulation of apoptotic process GO:0043066 9.91 TNFRSF18 NFKBIA MMP9 IL6 IL2RB IL2
5 response to lipopolysaccharide GO:0032496 9.87 NFKBIA JUN IL10 FOXP3
6 positive regulation of tumor necrosis factor production GO:0032760 9.83 IL6 IFNG CCL3
7 negative regulation of inflammatory response GO:0050728 9.83 IL2RA IL2 IL10 FOXP3
8 positive regulation of T cell proliferation GO:0042102 9.78 IL6 IL2RA IL2
9 positive regulation of inflammatory response GO:0050729 9.78 NFKBIA IL2 IFNG CCL3
10 positive regulation of interleukin-1 beta production GO:0032731 9.76 IL6 IFNG CCL3
11 cytokine-mediated signaling pathway GO:0019221 9.76 MMP9 IL6 IL2RB IL2RA IL2 IL10
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.73 MMP9 JUN IL10
13 interferon-gamma-mediated signaling pathway GO:0060333 9.73 TRIM5 IFNG HLA-B HLA-A
14 negative regulation of T cell proliferation GO:0042130 9.72 IL2RA IL10 FOXP3
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 TNFRSF18 IL6 IL2 IFNG
16 detection of bacterium GO:0016045 9.65 HLA-B HLA-A
17 T cell chemotaxis GO:0010818 9.65 CXCR3 CCL3
18 regulation of neuroinflammatory response GO:0150077 9.65 MMP9 IL6
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.64 IL10 IFNG
20 negative regulation of T-helper 17 cell differentiation GO:2000320 9.64 IL2 FOXP3
21 negative regulation of lipid storage GO:0010888 9.63 NFKBIA IL6
22 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.63 HLA-B HLA-A
23 positive regulation of immunoglobulin production GO:0002639 9.63 IL6 IL2 IL10
24 cytoplasmic sequestering of NF-kappaB GO:0007253 9.62 NFKBIA IL10
25 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.62 HLA-B HLA-A
26 protection from natural killer cell mediated cytotoxicity GO:0042270 9.58 HLA-B HLA-A
27 regulation of T cell anergy GO:0002667 9.54 HLA-B FOXP3
28 positive regulation of plasma cell differentiation GO:1900100 9.51 IL2 IL10
29 interleukin-2-mediated signaling pathway GO:0038110 9.5 IL2RB IL2RA IL2
30 regulation of T cell homeostatic proliferation GO:0046013 9.49 IL2RA IL2
31 negative regulation of lymphocyte proliferation GO:0050672 9.43 IL2RA IL2 FOXP3
32 regulation of regulatory T cell differentiation GO:0045589 9.35 TNFRSF18 IL2RA IL2 IFNG FOXP3
33 immune response GO:0006955 9.32 KIR2DL3 IL6 IL2RA IL2 IL10 IFNG

Molecular functions related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.61 TRIM5 NFKBIA MMP9 KIR2DL3 JUN FOXP3
2 TAP binding GO:0046977 9.32 HLA-B HLA-A
3 interleukin-2 binding GO:0019976 9.26 IL2RB IL2RA
4 interleukin-2 receptor activity GO:0004911 9.16 IL2RB IL2RA
5 cytokine activity GO:0005125 9.1 IL6 IL2 IL10 IFNL3 IFNG CCL3

Sources for Tropical Spastic Paraparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....